For many patients, it starts with a little back pain and urine discoloration — symptoms that are easy to ignore and very forgettable.
But, either quickly or over time, the back pain becomes chronic and the discolored urine alarming. Those early signs of bladder cancer aren’t easily detectable. That’s why it’s such a sneaky disease. And that’s why type 2 diabetes patients taking Actos need to be on the alert.
The FDA warns about Actos and bladder cancer to type 2 diabetes patients taking the drug. Other alarming Actos side effects include bone fractures, degenerative eye disease and congestive heart failure.
Actos: The Next Great Diabetes Drug?
Introduced in the United States in 1999, Actos was supposed to be the next great drug to treat type 2 diabetes. The drug’s inventor and manufacturer, Takeda Pharmaceuticals, said Actos helps increase the body’s sensitivity to insulin, a hormone produced in the pancreas that controls blood sugar levels. It was supposed to lower the risk of of heart problems.
As is the case with many drugs, the marketing hype did not match the reality.
Actos belongs to the much-maligned class of drugs called thiazolidinediones. Of the three drugs in its class — Actos, Avandia and Rezulin — Actos is the only drug that remains on the market.
The other two have been either recalled or severely restricted because of their detrimental health effects. All three drugs are known to work in the same manner.
Actos Remains on the Market Despite Alarming Health Concerns
Although initial clinical trials showed that Actos may be linked to bladder cancer, the U.S. Food and Drug Administration (FDA) allowed the drug on to the market with the stipulation that further testing be conducted. Takeda started its 10-year look into the bladder cancer risk in 2002. When the first five years of that study showed a 40 percent increased risk of bladder cancer for those taking Actos longer than a year, a firestorm of controversy erupted.
French and German drug regulators responded by recalling the drug. In the United States, the FDA put a new warning on the drug label. The end of the study, which comes in late 2012, coincides with Takeda losing its exclusive patent on Actos sales and the windfall that comes with it.
Coincidence? Perhaps not.
Some Doctors Refuse to Prescribe Actos
For many U.S. medical specialists, the FDA’s response was not strong enough, so they took matters into their own hands. Doctors yanked their patients off the drug, switching them to more trusted medicines like metformin.
Other researchers decided not to wait to see what Takeda’s study would show in the end, instead starting independent studies of their own. One such study, completed in May 2012 by Canadian researchers, found that the risk is much higher than first believed — Actos patients face an 80 percent increase in the risk of bladder cancer over those taking other diabetes medications.
When you add the bladder cancer risk to the drug’s propensity to cause congestive heart failure, it truly is a recipe for a medical disaster.